BBO-10203, an orally bioavailable small molecule that disrupts the RAS:PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer

BBO-11818, an orally bioavailable, highly potent and non covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRASG12D and KRASG12V preclinical models

BBO-10203, a first-in-class breaker of the PI3Kα:RAS interaction, demonstrates in vitro and in vivo efficacy alone or in combination with standard-of-care therapies in solid tumor models

BBO-8520, a first-in-class, direct, and covalent small molecule inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, demonstrates robust efficacy and compares favorably to GDP-bound KRASG12C (OFF) only inhibitors in preclinical models

BBO-8520, a First-in-Class, Direct Inhibitor of KRASG12C (ON), Locks GTP-Bound KRASG12C in the State 1 Conformation Resulting in Rapid and Complete Blockade of Effector Binding